ALNYLAM PHARMACEUTICALS INC

NASDAQ: ALNY (Alnylam Pharmaceuticals, Inc.)

Last update: 10 Feb, 4:00PM

170.03

0.53 (0.31%)

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Bullish
Biotechnology (Global) Bullish Bullish
Stock Alnylam Pharmaceuticals, Inc. - -

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Sector Healthcare
Industry Biotechnology
Investment Style Mid Growth
52 Weeks Range
148.10 - 227.91
Price Target Range
161.00 - 235.00
High 235.00 (RBC Capital, 38.21%) Outperform
Median 176.00 (3.51%)
Low 161.00 (Wells Fargo, -5.31%) Equal Weight
Average 192.44 (13.18%)
Total 2 Equal Weight, 3 Neutral, 3 Buy, 1 Outperform
Firm Date Target Price Call Price @ Call
RBC Capital 21 Feb 2024 235.00 (38.21%) Outperform 154.74
20 Feb 2024 235.00 (38.21%) Outperform 149.69
Cantor Fitzgerald 20 Feb 2024 165.00 (-2.96%) Neutral 149.69
15 Feb 2024 165.00 (-2.96%) Neutral 147.43
Chardan Capital 16 Feb 2024 225.00 (32.33%) Buy 147.00
Citigroup 16 Feb 2024 227.00 (33.51%) Buy 147.00
Goldman Sachs 16 Feb 2024 173.00 (1.75%) Neutral 147.00
Wells Fargo 16 Feb 2024 161.00 (-5.31%) Equal Weight 147.00
Needham 15 Feb 2024 200.00 (17.63%) Buy 147.43
Morgan Stanley 13 Feb 2024 176.00 (3.51%) Equal Weight 162.00
JP Morgan 01 Feb 2024 170.00 (-0.02%) Neutral 174.92
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
GARG PUSHKAL 147.43 147.00 2,987 440,936
GREENSTREET YVONNE 147.43 147.00 9,923 1,465,971
POULTON JEFFREY V. 147.43 147.00 2,271 335,247
TANGULER TOLGA 147.43 147.00 2,269 334,953
Aggregate Net Quantity 17,450
Aggregate Net Value ($) 2,577,106
Aggregate Avg. Buy ($) 147.43
Aggregate Avg. Sell ($) 147.00
Name Holder Date Type Quantity Price Value ($)
GREENSTREET YVONNE Officer 16 Feb 2024 Sell (-) 7,030 147.00 1,033,410
TANGULER TOLGA Officer 16 Feb 2024 Sell (-) 1,009 147.00 148,323
POULTON JEFFREY V. Officer 16 Feb 2024 Sell (-) 1,007 147.00 148,029
GARG PUSHKAL Officer 16 Feb 2024 Sell (-) 1,308 147.00 192,276
GREENSTREET YVONNE Officer 15 Feb 2024 Acquired (+) 16,953 147.43 2,499,381
TANGULER TOLGA Officer 15 Feb 2024 Acquired (+) 3,278 147.43 483,276
POULTON JEFFREY V. Officer 15 Feb 2024 Acquired (+) 3,278 147.43 483,276
GARG PUSHKAL Officer 15 Feb 2024 Acquired (+) 4,295 147.43 633,212
Date Type Details
29 Jan 2024 Announcement Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
09 Jan 2024 Announcement Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
07 Jan 2024 Announcement Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
02 Jan 2024 Announcement Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
13 Dec 2023 Announcement Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
06 Dec 2023 Announcement Alnylam to Webcast Virtual R&D Day
30 Nov 2023 Announcement Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
11 Nov 2023 Announcement Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
07 Nov 2023 Announcement Alnylam to Webcast Presentations at Upcoming November Investor Conferences
02 Nov 2023 Announcement Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
26 Oct 2023 Announcement Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
25 Oct 2023 Announcement Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
25 Oct 2023 Announcement Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
19 Oct 2023 Announcement Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
09 Oct 2023 Announcement Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
06 Oct 2023 Announcement Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
13 Sep 2023 Announcement Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
13 Sep 2023 Announcement Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
07 Sep 2023 Announcement Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
06 Sep 2023 Announcement First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
Show more

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data